Analysis of published datasets, using the Web-based Oncomine platform, reveals that BRF2 was amongst the top 1 % of genes overexpressed in a study [25] of 154 invasive breast carcinomas (p = 3.53E-10), whilst a larger study of over two thousand breast samples [26] confirmed BRF2 overexpression in several tumor subgroups, with invasive ductal breast carcinomas the most significant (p = 2.17E-21). This evidence concerns the gene BRF2 and neoplasm.